Clinical Trial: Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver Mutations

U.S., Sept. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07829744) titled 'Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver Mutations' on Sept. 15.

Brief Summary: This study evaluates the effectiveness and safety of targeted therapy given before and after surgery in patients with resectable or potentially resectable stage III non-small cell lung cancer with selected genetic alterations. Treatment is assigned according to tumor genetic findings.

Study Start Date: Sept. 20

Study Type: INTERVENTIONAL

Condition: Lung Cancer (NSCLC)

Intervention: PROCEDURE: Surgical Resection

Curative-intent resection following targeted therapy ...